Home > Drug List > Anamorelin > Precautions of Anamorelin

Precautions of Anamorelin

1. Important basic precautions

(1) Anamolin hydrochloride has a sodium channel inhibitory effect and has an inhibitory effect on the stimulation conduction system. Administration of Anamolin Hydrochloride may result in abnormal electrocardiograms (significant PR or QRS interval prolongation, QT interval prolongation, etc.). Therefore, regular measurements of electrocardiograms, pulse, blood pressure, cardiothoracic ratio, electrolytes, etc. should be taken before and during administration. If abnormalities are found, medication should be stopped. Additionally, special attention should be paid during the initial administration of Anamolin hydrochloride.

(2) High blood glucose levels should be measured regularly before and during the administration of Anamoxin Hydrochloride.

(3) Liver function damage may occur, and regular liver function tests should be performed before and during medication.

2. Precautions for patients with specific backgrounds

(1) May inhibit the heart function of patients with underlying heart disease (valve disease, cardiomyopathy, etc.), leading to worsening symptoms.

(2) Patients with a history of myocardial obstruction or angina may experience cardiac dysfunction, leading to worsening symptoms.

(3) Due to its sodium channel inhibitory effect, Anamolin hydrochloride may have inhibitory effects on the stimulation conduction system, leading to worsening of the condition in patients with stimulation conduction disorders (atrioventricular block, sinoatrial node, bundle branch conduction, etc.).

(4) Patients with a history of QT interval prolongation may experience QT interval prolongation.

(5) Patients with electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) may experience inhibition of the stimulation conduction system.

(6) Due to the cumulative cardiotoxicity of anthracyclines, individuals with a history of using anthracyclines may experience serious side effects.

(7) Sometimes it can make the blood sugar of diabetes patients rise.

(8) Patients with mild liver dysfunction (Child Pugh subtype A) should pay special attention when using moderate CYP3A4 inhibitors in combination. Due to the fact that the liver is mainly involved in the in vivo metabolism of Anabolin hydrochloride, there may be an increase in blood drug concentration, which may lead to inhibition of the stimulation conduction system. In addition, if moderate CYP3A4 inhibitors are used simultaneously, the metabolism of Anabolin hydrochloride is hindered, and there is a possibility of further increase in blood drug concentration.

fromJP,2023.02